BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, May 14, 2024
See today's BioWorld Asia
Home
» Microconstants moving into mAb space, picking up candidates from IBP
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Microconstants moving into mAb space, picking up candidates from IBP
Feb. 4, 2015
By
Cornelia Zou
No Comments
HONG KONG – A Chinese clinical trial site management organization (SMO) is getting into monoclonal antibodies (mAbs) after acquiring the global development and licensing rights of drug candidates developed by Chinese academic researchers.
BioWorld Asia